The FDA’s authorization of ZYN nicotine pouches as modified risk tobacco products puts Philip Morris International (NYSE:PM) in the spotlight, as investors weigh what this new regulatory status could mean for the stock.

The ZYN ruling lands at a time when Philip Morris International’s share price has gained 22.30% over the past 90 days and 20.39% year to date. The 3 year total shareholder return of 125.02% and 5 year total shareholder return of 147.74% point to momentum that long term holders will be weighing against today’s US$192.98 share price and evolving risk profile.

If this regulatory move has you reassessing opportunities in tobacco and beyond, it could be a good moment to widen your search and review 18 top founder-led companies

Bulls point to Philip Morris International’s shift to smoke-free products, strong cash generation, and the ZYN ruling, while bears focus on regulatory and valuation risks at US$192.98. Which side does the current valuation lean toward?

Most Popular Narrative: 10% Undervalued

Philip Morris International’s most followed narrative pegs fair value at $193.14, almost exactly in line with the current $192.98 share price, yet still frames the stock as modestly undervalued once discounted back using its chosen rate.

The accelerating global adoption of smoke-free alternatives, driven by increasing health awareness and regulatory moves away from combustibles, is fueling strong double-digit volume and margin growth in PMI's IQOS, ZYN, and VEEV platforms. This secular shift enables the company to capture new consumer segments, expand its addressable market, and structurally boost net revenues and operating margins over time.

Curious how that shift into IQOS, ZYN and VEEV turns into a higher fair value for Philip Morris International? The narrative leans on steady top line expansion, widening margins and a future earnings multiple that sits above the broader tobacco peer group. The detailed numbers behind those assumptions are where the real story is hiding.

Result: Fair Value of $193.14 (ABOUT RIGHT)

However, this Philip Morris International narrative still hinges on cigarette volume declines, as well as shifting regulations around smoke free products not tightening faster than expected.

Another View: Philip Morris International Through the P/E Lens

While the Philip Morris International narrative suggests fair value near today’s price, the current P/E of 27.2x paints a more demanding picture. It sits above the peer average of 22x and above an estimated fair ratio of 25.4x, which implies less margin for error if expectations change.

For investors weighing that premium against the ZYN ruling and smoke free growth story, it is worth asking whether the market is already paying tomorrow’s price for today’s earnings, or if this premium could prove resilient.

Next Steps

If the mixed signals around Philip Morris International leave you on the fence, now is a good time to review the full picture for yourself and weigh both sides of the argument. Start by looking at the balance of potential upsides and concerns in the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Philip Morris International?

If Philip Morris International is already on your radar, do not stop there. Broaden your watchlist with other opportunities that could sharpen your overall portfolio positioning.

• Target potential mispricings by scanning for companies that combine quality fundamentals with appealing valuations using the 47 high quality undervalued stocks.
• Strengthen your income stream by checking out stocks that offer resilient yields and robust payout histories through the 8 dividend fortresses.
• Reduce portfolio stress by focusing on companies with steadier risk profiles and fewer red flags via the 84 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.